Ensoma Announces Closing of Twelve Bio Acquisition

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: March 26, 2023

NATIONAL VISION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Aga • Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference • ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B • Build community with shared future, create better world • Philadelphia Works Names First Female Chief Operating Officer • ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting • Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates • Statement from the Chief Public Health Officer of Canada on World TB Day • SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI • National University Receives 2023 Military Friendly® Gold Designation • SBNY LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Signature Bank Investors to Secure Counsel Before Important D • Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges • HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers • Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail • SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los • GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office • SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t • SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote • DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio • Korelya Capital Invests in Weo, Bringing Total Funds Raised to $15M, and Leads Launch of its Series A Financing Round

Ensoma Announces Closing of Twelve Bio Acquisition

BOSTON , February 09 /Businesswire/ - Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within, today announced the closing of its previously announced acquisition of Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. The closing follows recent clearance by the Danish Business Authority pursuant to Danish foreign direct investment laws.

In conjunction with the closing, Stefano Stella, Ph.D., co-founder of Twelve Bio, has joined the leadership team at Ensoma as vice president of gene editing. Additionally, Guillermo Montoya, Ph.D., co-founder of Twelve Bio, and Shengdar Q. Tsai, Ph.D., a leading expert in genome engineering and hematology and member of the scientific advisory board of Twelve Bio, will join the scientific advisory board at Ensoma.

About Ensoma

Ensoma believes the future of medicine lies within us. The company’s Engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda and a passionate team committed to a bold, global vision for genomic medicine. Ensoma is headquartered in Boston, with additional research operations in Copenhagen, Denmark. For more information, visit ensoma.com.